Neurocrine Biosciences, Inc. (NBIX) News

Neurocrine Biosciences, Inc. (NBIX): $148.73

1.15 (+0.78%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

A

Add NBIX to Watchlist
Sign Up

Filter NBIX News Items

NBIX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NBIX News Highlights

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

Latest NBIX News From Around the Web

Below are the latest news stories about NEUROCRINE BIOSCIENCES INC that investors may wish to consider to help them evaluate NBIX as an investment opportunity.

Exploring High Growth Tech Stocks in January 2025

The United States market has remained flat over the past week but has experienced a notable 23% increase over the last year, with earnings anticipated to grow by 15% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability, aligning well with current market conditions and future earnings expectations.

Yahoo | January 9, 2025

Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a narrative review discussing the challenges of traditional treatment of classic congenital adrenal hyperplasia (CAH) with glucocorticoids (GCs) alone and the potential benefits of introducing novel non-GC mechanisms for treating the condition that may enable lower, more physiologic GC dosing. The publication appears in Expert Review of Endocrinology & Metabolism.

Yahoo | January 8, 2025

Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 43rd Annual J.P. Morgan Healthcare Conference at 8:15 a.m. Pacific Time on Monday January 13, 2025 in San Francisco. Kyle Gano, Chief Executive Officer, will present at the conference.

Yahoo | January 6, 2025

Neurocrine Biosciences Stock Sees RS Rating Upgrade

A Relative Strength Rating upgrade for Neurocrine Biosciences shows improving technical performance. Will it continue?

Yahoo | December 24, 2024

Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last?

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Yahoo | December 23, 2024

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced CRENESSITY™ (crinecerfont) is now commercially available in the United States. CRENESSITY was recently approved by the U.S. Food and Drug Administration as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH).

Yahoo | December 20, 2024

Neurocrine Jumps After Snagging FDA Approval For A First-In-Decades Drug

Neurocrine Biosciences stock jumped Monday after the company won FDA approval for the first new treatment for an adrenal disease in decade

Yahoo | December 16, 2024

Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential

On Friday, the FDA approved Neurocrine Biosciences, Inc.(NASDAQ:NBIX) Crenessity (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH). CAH is a rare, inherited disorder that affects the adrenal glands and causes them to be larger than normal. The adrenal glands are located above the kidneys and produce hormones that regul

Yahoo | December 16, 2024

Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved CRENESSITY™ (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH), a rare, serious and lifelong genetic condition involving the adrenal glands. CRENESSITY, a potent and selective oral corticotropin-releasing facto

Yahoo | December 13, 2024

Exploring Three High Growth Tech Stocks In The United States

Over the last 7 days, the United States market has remained flat, yet it is up 30% over the past year with earnings forecasted to grow by 15% annually. In this context of robust growth potential, identifying high growth tech stocks that align with these positive trends can be key for investors seeking opportunities in an evolving market landscape.

Yahoo | December 11, 2024


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!